Adma Biologics, Inc.

Adma Biologics, Inc. company information, Employees & Contact Information

ADMA Biologics is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. ADMA currently manufactures and markets three United States Food and Drug Administration (FDA) approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: BIVIGAM® (immune globulin intravenous, human) for the treatment of primary humoral immunodeficiency (PI); ASCENIV™ (immune globulin intravenous, human – slra 10% liquid) for the treatment of PI; and NABI-HB® (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. ADMA manufactures its immune globulin products at its FDA-licensed plasma fractionation and purification facility located in Boca Raton, Florida. Through its ADMA BioCenters subsidiary, ADMA also operates as an FDA-approved source plasma collector in the U.S., which provides a portion of its blood plasma for the manufacture of its products. ADMA’s mission is to manufacture, market and develop specialty plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases and management of immune compromised patient populations who suffer from an underlying immune deficiency, or who may be immune compromised for other medical reasons. ADMA has received U.S. Patents: 9,107,906, 9,714,283, 9,815,886, 9,969,793 and 10,259,865 related to certain aspects of its products and product candidates. For more information, please visit www.admabiologics.com.

Company Details

Employees
411
Founded
-
Address
465 Route 17 South, Ramsey,nj 07446,united States
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Ramsey, NJ
Looking for a particular Adma Biologics, Inc. employee's phone or email?

Adma Biologics, Inc. Questions

News

ADMA Biologics to Report Second Quarter 2025 Financial Results on August 6, 2025 - GlobeNewswire

ADMA Biologics to Report Second Quarter 2025 Financial Results on August 6, 2025 GlobeNewswire

ADMA Biologics Earnings: Biopharma Leader Sets Q2 2025 Financial Results Release for August 6 - Stock Titan

ADMA Biologics Earnings: Biopharma Leader Sets Q2 2025 Financial Results Release for August 6 Stock Titan

ADMA Biologics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - Yahoo Finance

ADMA Biologics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update Yahoo Finance

ADMA Biologics Receives FDA Approval for Innovative Yield Enhancement Process, Paving the Way for Increased Production Capacity and Revenue Growth - Nasdaq

ADMA Biologics Receives FDA Approval for Innovative Yield Enhancement Process, Paving the Way for Increased Production Capacity and Revenue Growth Nasdaq

ADMA Biologics: Strong Product Mix, Growing Margins & Compelling Upside (NASDAQ:ADMA) - Seeking Alpha

ADMA Biologics: Strong Product Mix, Growing Margins & Compelling Upside (NASDAQ:ADMA) Seeking Alpha

ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire

ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update GlobeNewswire

ADMA Biologics Announces Preliminary Full Year 2024 Revenue and Provides Business Update - Yahoo Finance

ADMA Biologics Announces Preliminary Full Year 2024 Revenue and Provides Business Update Yahoo Finance

ADMA Biologics Achieves Industry First: FDA Green Lights Revolutionary 20% Plasma Yield Enhancement - Stock Titan

ADMA Biologics Achieves Industry First: FDA Green Lights Revolutionary 20% Plasma Yield Enhancement Stock Titan

ADMA Biologics: A Better Quarter Than Headline Numbers (NASDAQ:ADMA) - Seeking Alpha

ADMA Biologics: A Better Quarter Than Headline Numbers (NASDAQ:ADMA) Seeking Alpha

ADMA Biologics Announces Partial Paydown of Senior Term Loan Credit Facility - Yahoo Finance

ADMA Biologics Announces Partial Paydown of Senior Term Loan Credit Facility Yahoo Finance

ADMA Biologics Announces First Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire

ADMA Biologics Announces First Quarter 2025 Financial Results and Provides Business Update GlobeNewswire

ADMA Biologics Announces Third Quarter 2024 Financial Results and Provides Business Update - Yahoo Finance

ADMA Biologics Announces Third Quarter 2024 Financial Results and Provides Business Update Yahoo Finance

ADMA Biologics: Slowing Growth Warrants A Shift To Neutral (Rating Downgrade) - Seeking Alpha

ADMA Biologics: Slowing Growth Warrants A Shift To Neutral (Rating Downgrade) Seeking Alpha

ADMA Biologics Announces Second Quarter 2024 Financial Results and Provides Business Update - Yahoo Finance

ADMA Biologics Announces Second Quarter 2024 Financial Results and Provides Business Update Yahoo Finance

ADMA Biologics: Recent Pullback Is A Perfect Opportunity To Add (NASDAQ:ADMA) - Seeking Alpha

ADMA Biologics: Recent Pullback Is A Perfect Opportunity To Add (NASDAQ:ADMA) Seeking Alpha

ADMA BioCenters Receives FDA Approval for its Eighth Plasma Collection Center, Located in Hammond, LA - Yahoo Finance

ADMA BioCenters Receives FDA Approval for its Eighth Plasma Collection Center, Located in Hammond, LA Yahoo Finance

ADMA Biologics Enters Into $100 Million Credit Facility Loan Amendment with Perceptive Advisors - GlobeNewswire

ADMA Biologics Enters Into $100 Million Credit Facility Loan Amendment with Perceptive Advisors GlobeNewswire

Is Adma Biologics (ADMA) a Buy as Wall Street Analysts Look Optimistic? - Yahoo Finance

Is Adma Biologics (ADMA) a Buy as Wall Street Analysts Look Optimistic? Yahoo Finance

ADMA - Adma Biologics Latest Stock News & Market Updates - Stock Titan

ADMA - Adma Biologics Latest Stock News & Market Updates Stock Titan

FDA Approves ASCENIV™, a Novel Intravenous Immune Globulin - GlobeNewswire

FDA Approves ASCENIV™, a Novel Intravenous Immune Globulin GlobeNewswire

ADMA Biologics Inc (ADMA) Q4 2020 Earnings Call Transcript - The Motley Fool

ADMA Biologics Inc (ADMA) Q4 2020 Earnings Call Transcript The Motley Fool

Novel Intravenous Immune Globulin Receives FDA Approval - Pharmacy Times

Novel Intravenous Immune Globulin Receives FDA Approval Pharmacy Times

Top Adma Biologics, Inc. Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant